Long on Meds Blog

Can Suppressing Inflammation Promote Healthy Aging?

By Mark Gostine, MD

Chronic inflammation contributes to many diseases associated with aging. Several medications that reduce inflammatory activity have also demonstrated meaningful health benefits in human clinical trials.

Could reducing chronic inflammation help us remain healthier, stronger, and more independent as we age? Research involving familiar medications provides encouraging evidence, particularly for cardiovascular health. Whether these benefits extend to slowing biological aging is an important question.

1. Do Medications That Suppress Inflammation in the Laboratory Also Reduce Inflammatory Markers in Humans?

Yes. Several randomized clinical trials have demonstrated measurable reductions in inflammation.

A commonly used blood marker is high sensitivity C-reactive protein (hsCRP), a protein produced by the liver in response to inflammation.

Rosuvastatin reduced hsCRP by approximately 37% in the JUPITER trial, involving more than 17,800 participants.

Low dose doxycycline, given at 20 milligrams twice daily, reduced median inflammatory markers in a two year trial involving women with periodontal disease. Researchers also documented reductions in an enzyme associated with tissue breakdown.

Semaglutide substantially reduced hsCRP in the SELECT trial, with a subsequent analysis showing a 37.8% reduction relative to placebo at 104 weeks.

Tirzepatide has also demonstrated reductions in inflammatory markers in patients with obesity and related cardiovascular disease.

These studies show that laboratory findings can translate into measurable biological changes in humans. However, lowering an inflammatory marker does not by itself prove that a medication prevents disease.

2. Have Clinical Trials Shown That These Medications Reduce Disease or Improve Human Health?

Yes. Several major trials have demonstrated meaningful clinical benefits.

Colchicine: In the LoDoCo2 trial, involving 5,522 patients with chronic coronary artery disease, colchicine 0.5 milligrams daily reduced the relative risk of a combined group of cardiovascular events by 31%. The benefit was not reproduced in every population studied, including patients treated soon after a heart attack.

Rosuvastatin: In JUPITER, rosuvastatin reduced the relative risk of the primary combined cardiovascular outcome by 44%. Participants had elevated inflammatory markers despite relatively normal low density lipoprotein (LDL) cholesterol levels. Both cholesterol reduction and anti-inflammatory effects may have contributed.

Semaglutide: In SELECT, involving more than 17,600 people with established cardiovascular disease and overweight or obesity but without diabetes, major cardiovascular events occurred in 6.5% of treated patients compared with 8.0% receiving placebo.

Tirzepatide: In SUMMIT, involving patients with obesity and heart failure with preserved ejection fraction, cardiovascular death or worsening heart failure occurred in 9.9% receiving tirzepatide compared with 15.3% receiving placebo. Participants also experienced improvements in symptoms and physical functioning.

Pioglitazone: In IRIS, involving patients with insulin resistance and a previous stroke or transient ischemic attack, subsequent stroke or heart attack occurred in 9.0% of patients receiving pioglitazone compared with 11.8% receiving placebo.

Low dose doxycycline: Clinical evidence supports its ability to help limit periodontal tissue deterioration when combined with conventional treatment. Comparable clinical trials have not established that it prevents cardiovascular disease or extends lifespan.

These findings demonstrate that several medications with anti-inflammatory properties improve clinical outcomes in selected patients. The benefits may arise from several biological mechanisms operating together.

3. Could Reducing Chronic Inflammation Help Preserve Muscle Strength and Prevent Sarcopenia?

Possibly. Chronic inflammation is one of several biological processes contributing to sarcopenia, the progressive loss of muscle mass, strength, and function associated with aging.

Inflammatory chemicals can accelerate muscle protein breakdown, interfere with muscle repair, and impair the body's response to exercise and nutrition.

This makes medications that suppress inflammatory pathways interesting candidates for research into preserving muscle reserve.

However, the clinical evidence remains limited. We do not yet have convincing randomized trials showing that colchicine, low dose doxycycline, or rosuvastatin prevents age related sarcopenia in otherwise healthy adults.

Weight loss medications introduce another consideration. Semaglutide and tirzepatide improve metabolic health, but weight loss can also involve loss of lean body mass. Maintaining muscle requires particular attention to resistance exercise and adequate protein intake.

For now, regular strength training and appropriate nutrition remain the foundations of preserving muscle reserve.

4. Could Suppressing Inflammation Protect the Heart, Brain, Kidneys, and Other Organs?

There is substantial evidence for cardiovascular protection with some of these medications, while evidence for protection of other organs varies.

Heart and blood vessels: Inflammation contributes to arterial plaque formation and instability. Clinical trials involving colchicine, statins, and metabolic medications demonstrate important cardiovascular benefits in selected populations.

Brain: Chronic inflammatory signaling is involved in several neurodegenerative diseases. Experimental research suggests that medications affecting inflammatory pathways may influence processes involved in Alzheimer's disease, but the six medications discussed here have not been established as general treatments for preventing neurodegeneration.

Kidneys: Inflammation and tissue scarring contribute to chronic kidney disease. Some medications, including certain metabolic therapies, have demonstrated kidney benefits in selected patients. Whether those benefits are primarily due to suppressing inflammation is not fully established.

Muscles: Chronic inflammation may interfere with muscle maintenance and regeneration. Protecting muscle tissue through medication remains a promising research question rather than a proven preventive strategy.

These overlapping pathways suggest that medications developed for one disease may sometimes provide benefits in other organs.

5. Is There Evidence That Suppressing Inflammation Can Extend Healthy Lifespan?

There is evidence that treating certain inflammatory and metabolic conditions can reduce disease and improve important health outcomes. There is not yet convincing clinical evidence that prescribing these six medications solely to suppress inflammation extends lifespan in otherwise healthy people.

That distinction matters. Preventing a heart attack, reducing worsening heart failure, and protecting tissues are meaningful achievements. They may contribute to healthier aging even when a medication has not been proven to slow the fundamental biological aging process.

The broader opportunity is to investigate whether familiar medications can influence several pathways involved in age related deterioration.

But no medication is without risk. Colchicine can cause serious toxicity and drug interactions. Statins can produce muscle related adverse effects. Pioglitazone can cause fluid retention and fractures. Weight loss medications have their own adverse effects and require attention to nutrition and muscle preservation.

The Long on Meds approach is not simply about taking more medications. It is about recognizing potentially useful effects beyond a medication's original indication and determining whether those additional benefits justify its risks.

The most important question is whether carefully chosen medications, alongside exercise, nutrition, and control of established risk factors, can help preserve organ function and independence as we grow older.

That is an important direction for future research into healthy aging.

Selected Scientific References

1. Nidorf SM, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020. Original study.
2. Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008. Original study.
3. Payne JB, et al. Subantimicrobial Dose Doxycycline and Systemic Inflammatory Biomarkers. Journal of the American Dental Association. 2011. Original study.
4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. Original study.
5. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2025. Original study.
6. Kernan WN, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016. Original study.
7. Plutzky J, et al. Effect of Semaglutide on High Sensitivity C-Reactive Protein in SELECT. Circulation. 2026. Original study.

Medical information: This article is educational. Medication decisions should consider individual medical conditions, established indications, and potential risks.

Related reading: Which medications suppress chronic inflammation? and How do medications affect inflammatory pathways?.

Return to homepage